Clinical trials: Insulin Pump
Type 1 Diabetes Mellitus
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII)…
- Trial name
- HALO-117-406 (NCT03662334)
- Testing
- Rapid Acting insulin with pre-treatment of rHuPH20
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus, Pregnancy
Orchestra Pregnancy Observational Study in Poland
The aim of this project is to document the use of insulin pump therapy (CSII), including sensor augmented pump therapy (SAP), before, during and after pregnancy in women with type 1 Diabetes Mellitus benefiting from the Orchestra…
- Trial name
- NCT01779141
- Where
- 24 sites in Poland
- Volunteers
- 481 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Treated With Insulin
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting.
- Trial name
- NCT05238142
- Testing
- MiniMed™ 780G Insulin Pump system
- Where
- 31 sites in United States
- Volunteers
- 574 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study. The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and SmartGuard™in preventing…
- Trial name
- SMILE (NCT02733991)
- Testing
- MiniMed™640G and Suspend before low, MiniMed™640G
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 153 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Omnipod 5 System Compared to Pump Therapy
Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or…
- Trial name
- NCT05409131
- Testing
- Omnipod 5 System
- Where
- 14 sites in United States, France
- Volunteers
- 196 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Prospective, multi-center, single-arm study in adults and children ages 6 to 80 with type 1 diabetes to evaluate the safety of Lyumjev with Control-IQ technology to achieve labeling updates for Lyumjev and the t:slim X2 insulin…
- Trial name
- NCT05403502
- Testing
- t:slim X2 insulin pump with Control-IQ technology 1.5
- Where
- 13 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
This study evaluated a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study was conducted in participants with type 1 diabetes mellitus to investigate how the human body…
- Trial name
- NCT02703324
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
- Trial name
- ABC (NCT05243628)
- Testing
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily…
- Trial name
- OpT2mise (NCT01182493)
- Testing
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Where
- 36 sites in United States, Austria and 11 more
- Volunteers
- 331 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections.
- Trial name
- STAR2 (NCT00530023)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily…
- Trial name
- VIVID (NCT02561078)
- Testing
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 420 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study.
- Trial name
- NCT01134107
- Testing
- Insulin Lispro 6 Day (6D), Insulin Aspart 6 Day (6D)
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
MEDTRUM A7+ TouchCare Insulin Patch Pump (MedInPS)
Demonstration study of the interest of the MEDTRUM A7+ TouchCare insulin patch pump versus INSULET Omnipod® patch pump
- Trial name
- MedInPS (NCT04223973)
- Testing
- Medtrum A7+ insulin Pump, Lab A1C
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Medtrum France
Diabetes Type 1
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
- Trial name
- PRONTO-Pump (NCT03433677)
- Testing
- LY900014, Insulin lispro
- Where
- 5 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 620G and 640G Insulin Pumps
This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain.
- Trial name
- NCT01726621
- Testing
- Medtronic MiniMed 620G or 640G Insulin Pump
- Where
- 6 sites in Australia, Denmark and 2 more
- Volunteers
- 55 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-Pump-2 (NCT03830281)
- Testing
- Ultra-Rapid Lispro, Insulin Lispro
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company